NVO Stock Up as Amycretin Shows Strong Weight Loss in Type 2 Diabetes

Key Takeaways NVO reports amycretin drove notable weight loss versus placebo in type 2 diabetes patients.Subcutaneous and oral amycretin cut HbA1c levels by up to 1.8% and 1.5% by week 36, respectively.Both formulations were generally well tolerated, with phase III plans on amycretin set for 2026.Shares of Novo Nordisk (NVO) were up 4.7% yesterday, after the company announced positive data from a phase II study evaluating its investigational pipeline candidate, amycretin, in people with type 2 diabetes.The ...